Skip to main content
Top
Published in: Clinical Rheumatology 5/2019

01-05-2019 | Systemic Lupus Erythematosus | Original Article

Upregulated expression of STAT3/IL-17 in patients with systemic lupus erythematosus

Authors: Shih-Yao Chen, Ming-Fei Liu, Pin-Yu Kuo, Chrong-Reen Wang

Published in: Clinical Rheumatology | Issue 5/2019

Login to get access

Abstract

Elevated IL-17 levels with higher Th17 numbers are identified in systemic lupus erythematosus (SLE). STAT3 signaling plays a crucial role in the Th17 generation, and SOCS3 negatively regulates their formation. We investigated IL-17, STAT3, and SOCS3 expression, and analyzed their correlations to elucidate the regulatory mechanisms of IL-17 production in SLE. This study enrolled 32 patients, and venous mononuclear cells (MNCs) were isolated with further purification of CD4-positive T cells. IL-17 and SOCS3 levels were measured by real-time quantitative PCR, and pSTAT3/STAT3 expression was analyzed by immunoblot. Elevated IL-17 and SOCS3 levels were identified in lupus patients. There were higher IL-17 levels in lupus nephritis (class IV) than in SLE without renal involvement. Positive correlations were found between IL-17 levels and SOCS3 expression, lupus activity (SLEDAI-2K), or daily proteinuria. There were higher intensities of pSTAT3/β-actin and STAT3/β-actin in SLE, and a positive correlation between IL-17 expression and pSTAT3/β-actin or STAT3/β-actin intensity. Lupus nephritis (class IV) had higher STAT3/β-actin intensity than SLE without renal involvement. These results suggest upregulated STAT3/IL-17 expression in lupus patients. Such findings might facilitate the development of novel compounds and the application of existing therapeutics targeting the STAT3/IL-17 signal in SLE.
Literature
2.
go back to reference Shuai K, Liu B (2003) Regulation of JAK-STAT signaling in the immune system. Nat Rev Immunol 3(11):900–911CrossRefPubMed Shuai K, Liu B (2003) Regulation of JAK-STAT signaling in the immune system. Nat Rev Immunol 3(11):900–911CrossRefPubMed
3.
4.
go back to reference Liang Y, Xu WD, Peng H, Pan HF, Ye DQ (2014) SOCS signaling in autoimmune diseases: molecular mechanisms and therapeutic implications. Eur J Immunol 44(5):1265–1275CrossRefPubMed Liang Y, Xu WD, Peng H, Pan HF, Ye DQ (2014) SOCS signaling in autoimmune diseases: molecular mechanisms and therapeutic implications. Eur J Immunol 44(5):1265–1275CrossRefPubMed
5.
go back to reference Sukka-Ganesh B, Larkin J III (2016) Therapeutic potential for targeting the suppressor of cytokine signalling-1 pathway for the treatment of SLE. Scand J Immunol 84(5):299–309CrossRefPubMedPubMedCentral Sukka-Ganesh B, Larkin J III (2016) Therapeutic potential for targeting the suppressor of cytokine signalling-1 pathway for the treatment of SLE. Scand J Immunol 84(5):299–309CrossRefPubMedPubMedCentral
6.
go back to reference Chen Z, Laurence A, Kanno Y, Pacher-Zavisin M, Zhu BM, Tato C, Yoshimura A, Hennighausen L, O'Shea JJ (2006) Selective regulatory function of Socs3 in the formation of IL-17-secreting T cells. Proc Natl Acad Sci U S A 103(21):8137–8142CrossRefPubMedPubMedCentral Chen Z, Laurence A, Kanno Y, Pacher-Zavisin M, Zhu BM, Tato C, Yoshimura A, Hennighausen L, O'Shea JJ (2006) Selective regulatory function of Socs3 in the formation of IL-17-secreting T cells. Proc Natl Acad Sci U S A 103(21):8137–8142CrossRefPubMedPubMedCentral
7.
go back to reference Milner JD, Brenchley JM, Laurence A, Freeman AF, Hill BJ, Elias KM, Kanno Y, Spalding C, Elloumi HZ, Paulson ML, Davis J, Hsu A, Asher AI, O'Shea J, Holland SM, Paul WE, Douek DC (2008) Impaired T(H)17 cell differentiation in subjects with autosomal dominant hyper-IgE syndrome. Nature 452(7188):773–776CrossRefPubMedPubMedCentral Milner JD, Brenchley JM, Laurence A, Freeman AF, Hill BJ, Elias KM, Kanno Y, Spalding C, Elloumi HZ, Paulson ML, Davis J, Hsu A, Asher AI, O'Shea J, Holland SM, Paul WE, Douek DC (2008) Impaired T(H)17 cell differentiation in subjects with autosomal dominant hyper-IgE syndrome. Nature 452(7188):773–776CrossRefPubMedPubMedCentral
8.
go back to reference Hochberg MC (1997) Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 40(9):1725CrossRefPubMed Hochberg MC (1997) Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 40(9):1725CrossRefPubMed
9.
go back to reference Gladman DD, Ibañez D, Urowitz MB (2002) Systemic lupus erythematosus disease activity index 2000. J Rheumatol 29(2):288–291PubMed Gladman DD, Ibañez D, Urowitz MB (2002) Systemic lupus erythematosus disease activity index 2000. J Rheumatol 29(2):288–291PubMed
10.
go back to reference Pistiner M, Wallace DJ, Nessim S, Metzger AL, Klinenberg JR (1991) Lupus erythematosus in the 1980s: a survey of 570 patients. Semin Arthritis Rheum 21(1):55–64CrossRefPubMed Pistiner M, Wallace DJ, Nessim S, Metzger AL, Klinenberg JR (1991) Lupus erythematosus in the 1980s: a survey of 570 patients. Semin Arthritis Rheum 21(1):55–64CrossRefPubMed
11.
go back to reference Wang CR, Liu MF (2003) Regulation of CCR5 expression and MIP-1α production in CD4+ T cells from patients with rheumatoid arthritis. Clin Exp Immunol 132(2):371–378CrossRefPubMedPubMedCentral Wang CR, Liu MF (2003) Regulation of CCR5 expression and MIP-1α production in CD4+ T cells from patients with rheumatoid arthritis. Clin Exp Immunol 132(2):371–378CrossRefPubMedPubMedCentral
12.
go back to reference Peng JS, Chen SY, Wu CL, Chong HE, Ding YC, Shiau AL, Wang CR (2016) Amelioration of experimental autoimmune arthritis through targeting synovial fibroblasts by the intra-articular delivery of microRNA-140-3p and -5p. Arthritis Rheumatol 68(2):370–381CrossRefPubMed Peng JS, Chen SY, Wu CL, Chong HE, Ding YC, Shiau AL, Wang CR (2016) Amelioration of experimental autoimmune arthritis through targeting synovial fibroblasts by the intra-articular delivery of microRNA-140-3p and -5p. Arthritis Rheumatol 68(2):370–381CrossRefPubMed
13.
go back to reference Krebs CF, Panzer U (2018) Plasticity and heterogeneity of Th17 in immune-mediated kidney diseases. J Autoimmun 87:61–68CrossRefPubMed Krebs CF, Panzer U (2018) Plasticity and heterogeneity of Th17 in immune-mediated kidney diseases. J Autoimmun 87:61–68CrossRefPubMed
14.
go back to reference Liu MF, Wang CR (2014) Increased Th17 in flow cytometer-sorted CD45RO-positive memory CD4 T cells from patients with systemic lupus erythematosus. Lupus Sci Med 1(1):e000062CrossRefPubMedPubMedCentral Liu MF, Wang CR (2014) Increased Th17 in flow cytometer-sorted CD45RO-positive memory CD4 T cells from patients with systemic lupus erythematosus. Lupus Sci Med 1(1):e000062CrossRefPubMedPubMedCentral
15.
go back to reference Raychaudhuri SK, Saxena A, Raychaudhuri SP (2015) Role of IL-17 in the pathogenesis of psoriatic arthritis and axial spondyloarthritis. Clin Rheumatol 34(6):1019–1023CrossRefPubMed Raychaudhuri SK, Saxena A, Raychaudhuri SP (2015) Role of IL-17 in the pathogenesis of psoriatic arthritis and axial spondyloarthritis. Clin Rheumatol 34(6):1019–1023CrossRefPubMed
16.
go back to reference Satoh Y, Nakano K, Yoshinari H, Nakayamada S, Iwata S, Kubo S, Miyagawa I, Yoshikawa M, Miyazaki Y, Saito K, Tanaka Y (2018) A case of refractory lupus nephritis complicated by psoriasis vulgaris that was controlled with secukinumab. Lupus 27(7):1202–1206CrossRefPubMed Satoh Y, Nakano K, Yoshinari H, Nakayamada S, Iwata S, Kubo S, Miyagawa I, Yoshikawa M, Miyazaki Y, Saito K, Tanaka Y (2018) A case of refractory lupus nephritis complicated by psoriasis vulgaris that was controlled with secukinumab. Lupus 27(7):1202–1206CrossRefPubMed
17.
go back to reference O'She JJ, Holland SM, Staudt LM (2013) Mechanisms of JAK/STAT signaling in immunity and disease. N Engl J Med 368(2):161–170CrossRef O'She JJ, Holland SM, Staudt LM (2013) Mechanisms of JAK/STAT signaling in immunity and disease. N Engl J Med 368(2):161–170CrossRef
18.
go back to reference Harada T, Kyttaris V, Li Y, Juang YT, Wang Y, Tsokos GC (2007) Increased expression of STAT3 in SLE T cells contributes to enhanced chemokine-mediated cell migration. Autoimmunity 40(1):1–8CrossRefPubMed Harada T, Kyttaris V, Li Y, Juang YT, Wang Y, Tsokos GC (2007) Increased expression of STAT3 in SLE T cells contributes to enhanced chemokine-mediated cell migration. Autoimmunity 40(1):1–8CrossRefPubMed
19.
go back to reference Hedrich CM, Rauen T, Apostolidis SA, Grammatikos AP, Rodriguez Rodriguez N, Ioannidis C, Kyttaris VC, Crispin JC, Tsokos GC (2014) Stat3 promotes IL-10 expression in lupus T cells through trans-activation and chromatin remodeling. Proc Natl Acad Sci U S A 111(37):13457–13462CrossRefPubMedPubMedCentral Hedrich CM, Rauen T, Apostolidis SA, Grammatikos AP, Rodriguez Rodriguez N, Ioannidis C, Kyttaris VC, Crispin JC, Tsokos GC (2014) Stat3 promotes IL-10 expression in lupus T cells through trans-activation and chromatin remodeling. Proc Natl Acad Sci U S A 111(37):13457–13462CrossRefPubMedPubMedCentral
20.
go back to reference Edwards LJ, Mizui M, Kyttaris V (2015) Signal transducer and activator of transcription (STAT) 3 inhibition delays the onset of lupus nephritis in MRL/lpr mice. Clin Immunol 158(2):221–230CrossRefPubMedPubMedCentral Edwards LJ, Mizui M, Kyttaris V (2015) Signal transducer and activator of transcription (STAT) 3 inhibition delays the onset of lupus nephritis in MRL/lpr mice. Clin Immunol 158(2):221–230CrossRefPubMedPubMedCentral
21.
go back to reference Huang X, Guo Y, Bao C, Shen N (2011) Multidimensional single cell based STAT phosphorylation profiling identifies a novel biosignature for evaluation of systemic lupus erythematosus activity. PLoS One 6(7):e21671CrossRefPubMedPubMedCentral Huang X, Guo Y, Bao C, Shen N (2011) Multidimensional single cell based STAT phosphorylation profiling identifies a novel biosignature for evaluation of systemic lupus erythematosus activity. PLoS One 6(7):e21671CrossRefPubMedPubMedCentral
22.
go back to reference Goropevšek A, Holcar M, Avčin T (2017) The role of STAT signaling pathways in the pathogenesis of systemic lupus erythematosus. Clin Rev Allergy Immunol 52(2):164–181CrossRefPubMed Goropevšek A, Holcar M, Avčin T (2017) The role of STAT signaling pathways in the pathogenesis of systemic lupus erythematosus. Clin Rev Allergy Immunol 52(2):164–181CrossRefPubMed
23.
go back to reference Chikuma S, Kanamori M, Mise-Omata S, Yoshimura A (2017) Suppressors of cytokine signaling: potential immune checkpoint molecules for cancer immunotherapy. Cancer Sci 108(4):574–580CrossRefPubMedPubMedCentral Chikuma S, Kanamori M, Mise-Omata S, Yoshimura A (2017) Suppressors of cytokine signaling: potential immune checkpoint molecules for cancer immunotherapy. Cancer Sci 108(4):574–580CrossRefPubMedPubMedCentral
24.
go back to reference Liu K, Liang C, Liang Z, Tus K, Wakeland EK (2005) Sle1ab mediates the aberrant activation of STAT3 and Ras-ERK signaling pathways in B lymphocytes. J Immunol 174(3):1630–1637CrossRefPubMed Liu K, Liang C, Liang Z, Tus K, Wakeland EK (2005) Sle1ab mediates the aberrant activation of STAT3 and Ras-ERK signaling pathways in B lymphocytes. J Immunol 174(3):1630–1637CrossRefPubMed
25.
go back to reference Isomäki P, Alanärä T, Isohanni P, Lagerstedt A, Korpela M, Moilanen T, Visakorpi T, Silvennoinen O (2007) The expression of SOCS is altered in rheumatoid arthritis. Rheumatology 46(10):1538–1546CrossRefPubMed Isomäki P, Alanärä T, Isohanni P, Lagerstedt A, Korpela M, Moilanen T, Visakorpi T, Silvennoinen O (2007) The expression of SOCS is altered in rheumatoid arthritis. Rheumatology 46(10):1538–1546CrossRefPubMed
Metadata
Title
Upregulated expression of STAT3/IL-17 in patients with systemic lupus erythematosus
Authors
Shih-Yao Chen
Ming-Fei Liu
Pin-Yu Kuo
Chrong-Reen Wang
Publication date
01-05-2019
Publisher
Springer London
Published in
Clinical Rheumatology / Issue 5/2019
Print ISSN: 0770-3198
Electronic ISSN: 1434-9949
DOI
https://doi.org/10.1007/s10067-019-04467-8

Other articles of this Issue 5/2019

Clinical Rheumatology 5/2019 Go to the issue
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.